MY17

MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 0.41±0.05 μM. It alleviates insulin resistance induced by palmitic acid (PA) by enhancing the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT) . By binding to PTP1B, MY17 inhibits its activity, thereby improving insulin signaling and exhibiting antidiabetic properties. MY17 is useful in the study of type 2 diabetes.